Differentiation of true progression from pseudoprogression in glioblastoma treated with radiation therapy and concomitant temozolomide: Comparison study of standard and high-b-value diffusion-weighted imaging

Radiology

Volumn 269, Issue 3, 2013, Pages 831-840

  Chu, Hee Ho ^a   Choi, Seung Hong ^a   Ryoo, Inseon ^a   Kim, Soo Chin ^a   Yeom, Jeong A ^a   Shin, Hwaseon ^a   Jung, Seung Chai ^a   Lee, A Leum ^a   Yoon, Tae Jin ^a   Kim, Tae Min ^a   Lee, Se Hoon ^a   Park, Chul Kee ^a   Kim, Ji Hoon ^a   Sohn, Chul Ho ^a   Park, Sung Hye ^a   Kim, Il Han ^a  

^a Seoul National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

TEMOZOLOMIDE;

ADULT; ANALYTICAL PARAMETERS; APPARENT DIFFUSION COEFFICIENT MAP; ARTICLE; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER GROWTH; CANCER RADIOTHERAPY; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; DISEASE COURSE; GLIOBLASTOMA; HISTOGRAM; HISTOPATHOLOGY; HUMAN; INTERMETHOD COMPARISON; MIDDLE AGED; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; VALIDATION STUDY;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CHEMORADIOTHERAPY; DACARBAZINE; DIFFUSION MAGNETIC RESONANCE IMAGING; DISEASE PROGRESSION; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84890043532     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.13122024     Document Type: Article

References (33)

1. Jeon HJ, Kong DS, Park KB, et al. Clinical outcome of concomitant chemoradiotherapy followed by adjuvant temozolomide therapy for glioblastaomas: single-center experience. Clin Neurol Neurosurg 2009;111(8):679-682.
2. Brandes AA, Tosoni A, Spagnolli F, et al. Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology. Neuro-oncol 2008;10(3):361-367.
3. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352(10):987-996.
4. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8(7):1277-1280.
5. Kumar AJ, Leeds NE, Fuller GN, et al. Malignant gliomas: MR imaging spectrum of radiation therapy-and chemotherapy-induced necrosis of the brain after treatment. Radiology 2000;217(2):377-384.
6. Ulmer S, Braga TA, Barker FG 2nd, Lev MH, Gonzalez RG, Henson JW. Clinical and radiographic features of peritumoral infarction following resection of glioblastoma. Neurology 2006;67(9):1668-1670.
7. Taal W, Brandsma D, de Bruin HG, et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer 2008;113(2):405-410.
8. Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 2008;9(5):453-461.
9. Chaskis C, Neyns B, Michotte A, De Ridder M, Everaert H. Pseudoprogression after radiotherapy with concurrent temozolomide for high-grade glioma: clinical observations and working recommendations. Surg Neurol 2009;72(4):423-428.
10. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010;28(11):1963-1972.
11. Bammer R. Basic principles of diffusionweighted imaging. Eur J Radiol 2003;45(3): 169-184.
12. Burdette JH, Durden DD, Elster AD, Yen YF. High b-value diffusion-weighted MRI of normal brain. J Comput Assist Tomogr 2001;25(4):515-519.
13. Roth Y, Tichler T, Kostenich G, et al. Highb-value diffusion-weighted MR imaging for pretreatment prediction and early monitoring of tumor response to therapy in mice. Radiology 2004;232(3):685-692.
14. Kang Y, Choi SH, Kim YJ, et al. Gliomas: histogram analysis of apparent diffusion coefficient maps with standard-or highb-value diffusion-weighted MR imaging-correlation with tumor grade. Radiology 2011;261(3):882-890.
15. Hein PA, Eskey CJ, Dunn JF, Hug EB. Diffusion-weighted imaging in the follow-up of treated high-grade gliomas: tumor recurrence versus radiation injury. AJNR Am J Neuroradiol 2004;25(2):201-209.
16. Asao C, Korogi Y, Kitajima M, et al. Diffusion-weighted imaging of radiation-induced brain injury for differentiation from tumor recurrence. AJNR Am J Neuroradiol 2005;26(6):1455-1460.
17. Abdel Razek AA, Kandeel AY, Soliman N, et al. Role of diffusion-weighted echo-planar MR imaging in differentiation of residual or recurrent head and neck tumors and posttreatment changes. AJNR Am J Neuroradiol 2007;28(6):1146-1152.
18. Matsusue E, Fink JR, Rockhill JK, Ogawa T, Maravilla KR. Distinction between glioma progression and post-radiation change by combined physiologic MR imaging. Neuroradiology 2010;52(4):297-306.
19. Lee WJ, Choi SH, Park CK, et al. Diffusionweighted MR imaging for the differentiation of true progression from pseudoprogression following concomitant radiotherapy with temozolomide in patients with newly diagnosed high-grade gliomas. Acad Radiol 2012;19(11):1353-1361.
20. Tozer DJ, Jäger HR, Danchaivijitr N, et al. Apparent diffusion coefficient histograms may predict low-grade glioma subtype. NMR Biomed 2007;20(1):49-57.
21. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455(7216):1061-1068. [Published correction appears in Nature 2013;494(7438):506.]
22. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44(3):837-845.
23. Zeng QS, Li CF, Liu H, Zhen JH, Feng DC. Distinction between recurrent glioma and radiation injury using magnetic resonance spectroscopy in combination with diffusionweighted imaging. Int J Radiat Oncol Biol Phys 2007;68(1):151-158.
24. Padhani AR, Liu G, Koh DM, et al. Diffusionweighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 2009;11(2):102-125.
25. Sugahara T, Korogi Y, Kochi M, et al. Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas. J Magn Reson Imaging 1999;9(1):53-60.
26. Kong DS, Kim ST, Kim EH, et al. Diagnostic dilemma of pseudoprogression in the treatment of newly diagnosed glioblastomas: the role of assessing relative cerebral blood flow volume and oxygen-6-methylguanine-DNA methyltransferase promoter methylation status. AJNR Am J Neuroradiol 2011;32(2):382-387.
27. Murakami R, Hirai T, Sugahara T, et al. Grading astrocytic tumors by using apparent diffusion coefficient parameters: superiority of a one-versus two-parameter pilot method. Radiology 2009;251(3):838-845.
28. Higano S, Yun X, Kumabe T, et al. Malignant astrocytic tumors: clinical importance of apparent diffusion coefficient in prediction of grade and prognosis. Radiology 2006;241(3):839-846.
29. DeLano MC, Cooper TG, Siebert JE, Potchen MJ, Kuppusamy K. High-b-value diffusion-weighted MR imaging of adult brain: image contrast and apparent diffusion coefficient map features. AJNR Am J Neuroradiol 2000;21(10):1830-1836.
30. Niendorf T, Dijkhuizen RM, Norris DG, van Lookeren Campagne M, Nicolay K. Biexponential diffusion attenuation in various states of brain tissue: implications for diffusion-weighted imaging. Magn Reson Med 1996;36(6):847-857.
31. Mulkern RV, Gudbjartsson H, Westin CF, et al. Multi-component apparent diffusion coefficients in human brain. NMR Biomed 1999;12(1):51-62.
32. Maier SE, Bogner P, Bajzik G, et al. Normal brain and brain tumor: multicomponent apparent diffusion coefficient line scan imaging. Radiology 2001;219(3):842-849.
33. Seo HS, Chang KH, Na DG, Kwon BJ, Lee DH. High b-value diffusion (b = 3000 s/mm2) MR imaging in cerebral gliomas at 3T: visual and quantitative comparisons with b = 1000 s/mm2. AJNR Am J Neuroradiol 2008;29(3):458-463.